Nektar Therapeutics
NKTR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000906709
In the last 90 days, Nektar Therapeutics insiders filed 0 open-market purchases and 2 sales; 239 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Nektar Therapeutics changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Of which not filed for Q1 2024 | Q1 2024 | Change |
|---|---|---|---|---|
| Holders | 127 | 1 | 123 | −3 |
| Shares | 119.2M | 200 | 113.0M | −6.23M (−5.2%) |
| Value | $67.3M | $113 | $105.5M | +$38.2M (+56.7%) |
1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (16)
Institutions that held Nektar Therapeutics at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| TCG Crossover Management, LLC | 4,000,000 | $3.74M | 0.30% |
| Stonepine Capital Management, LLC | 3,480,409 | $3.25M | 2.58% |
| Nantahala Capital Management, LLC | 2,475,954 | $2.31M | 0.23% |
| Shay Capital LLC | 2,079,674 | $1.94M | 0.57% |
| Almitas Capital LLC | 920,225 | $859.7K | 0.36% |
| Y-Intercept (Hong Kong) Ltd | 127,564 | $119.2K | 0.01% |
| State Board of Administration of Florida Retirement System | 67,437 | $47.4K | 0.00% |
| Cetera Investment Advisers | 24,788 | $23.2K | 0.00% |
| Toroso Investments, LLC | 23,030 | $21.5K | 0.00% |
| First Trust Investment Solutions L.P. | 20,000 | $18.7K | 0.00% |
| Group One Trading, L.P. | 19,460 | $18.2K | 0.00% |
| Virtu Financial LLC | 16,748 | $16.0K | 0.00% |
| JustInvest LLC | 11,868 | $11.1K | 0.00% |
| GTS Securities LLC | 11,388 | $10.6K | 0.00% |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 200 | $186 | 0.00% |
| Assetmark, Inc | 22 | $21 | 0.00% |
Sold out (19)
Institutions that held Nektar Therapeutics at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Tang Capital Management LLC | 2,348,109 | $1.33M |
| XTX Topco Ltd | 73,212 | $41.4K |
| HRT Financial LP | 70,500 | $39.0K |
| Scientech Research LLC | 30,224 | $17.1K |
| Two Sigma Securities, LLC | 21,535 | $12.2K |
| Freestone Capital Holdings, LLC | 20,000 | $11.3K |
| Raymond James Financial Services Advisors, Inc. | 19,400 | $11.0K |
| Neuberger Berman Group LLC | 14,622 | $8.26K |
| Cetera Advisors LLC | 12,300 | $6.95K |
| Confluence Wealth Services, Inc. | 11,685 | $6.60K |
| Choate Investment Advisors | 11,580 | $6.54K |
| Tower Research Capital LLC (TRC) | 10,284 | $5.81K |
| Simplex Trading, LLC | 3,819 | $2.00K |
| Atlas Capital Advisors LLC | 600 | $339 |
| PFS Partners, LLC | 597 | $338 |
| The PNC Financial Services Group, Inc. | 100 | $57 |
| Advisory Services Network, LLC | 3 | $2 |
| McClarren Financial Advisors, Inc. | 157 | $0 |
| Ronald Blue Trust, Inc. | 362 | $0 |
Not filed for Q1 2024 yet (1)
Institutions that held Nektar Therapeutics at the end of Q4 2023 and haven't filed a 13F for Q1 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Strategic Investment Solutions, Inc. | 200 | $113 |